公开(公告)号：US20230227435A1

公开(公告)日：2023-07-20

申请号：US18002080

申请日：2021-06-17

Applicant: LEO PHARMA A/S

Inventor： Mark ANDREWS ,  Kevin Neil DACK ,  Jimmi Gerner SEITZBERG ,  Peter ANDERSEN

IPC: C07D403/12 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D405/14

CPC classification number: C07D403/12 ,  C07D401/14 ,  C07D403/14 ,  C07D413/14 ,  C07D405/14

Abstract: The present disclosure relates to compounds according to formula I






and pharmaceutically acceptable salts, hydrates, or solvates thereof. The disclosure further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

公开(公告)号：US20240208938A1

公开(公告)日：2024-06-27

申请号：US18526149

申请日：2023-12-01

Applicant: LEO Pharma A/S

Inventor： Mark ANDREWS ,  Mogens LARSEN ,  Alan JESSIMAN ,  Patrick JOHNSON ,  Kevin Neil DACK

IPC: C07D401/14

CPC classification number: C07D401/14

Abstract: The present invention relates to a compound according to formula (I)




and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g., dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

公开(公告)号：US20180258080A1

公开(公告)日：2018-09-13

申请号：US15759622

申请日：2016-09-13

Applicant: LEO Pharma A/S

Inventor： Patrick Stephen JOHNSON ,  Kevin Neil DACK ,  Krister HENRIKSSON

IPC: C07D405/06 ,  C07D405/14 ,  A61K31/4545 ,  C07D417/14 ,  C07D413/14 ,  A61K31/4525 ,  A61K31/454

CPC classification number: C07D405/06 ,  A61K31/4525 ,  A61K31/454 ,  A61K31/4545 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14

Abstract: The present invention relates to a compound according to formula (I) wherein R1 is selected from the group consisting of 5- and 6-membered heteroaryl, (C1-C6)alkyl, (C3-C6)cycloalkyl, (4-6)-membered heterocycloalkyl and phenyl; R2 is selected from (C1-C3)alkyl and halo(C1-C3)alkyl; R3 is selected from phenyl, 5-membered heteroaryl and 6-membered heteroaryl; R4 is selected from hydrogen, halogen, (C1-C4)alkyl and halo(C1-C4)alkyl; X1 is selected from CH, C(Rb) and N, X2 is selected from CH and N; Y is selected from —NH— and —O—; m is 0 or 1; n is 0 or 1; L represents a bond, —O—, —NH— or —N(Rc)—; or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to intermediates for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases with said compounds, and to the use of said compounds in the manufacture of medicaments.

公开(公告)号：US20220162191A1

公开(公告)日：2022-05-26

申请号：US17436885

申请日：2020-03-06

Applicant: LEO PHARMA A/S

Inventor： Xifu LIANG ,  Kevin Neil DACK ,  Peter ANDERSEN ,  Morten Dahl SØRENSEN ,  Mark ANDREWS ,  Alan Stuart JESSIMAN

IPC: C07D403/12 ,  C07D401/14 ,  C07D401/12 ,  C07D413/14 ,  C07D471/08 ,  C07D417/14 ,  C07D491/107 ,  C07D491/048 ,  C07D403/14 ,  C07D405/14

Abstract: The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.